COVID-19 Clinical Care: Canadian Medical Assocation Warns Of Potential Dangers Of Chloroquine, Hydroxychloroquine And Azithromycin For COVID-19 Treatment
COVID-19 Clinical Care: Chloroquine, hydroxychloroquine and azithromycin are being used to ‘treat and prevent’ COVID-19 despite extremely little and weak evidence for effectiveness, and doctors, healthcare professionals and patients should be aware of these drugs' potentially serious adverse events, states a new report and announcement in
CMAJ (
Canadian Medical Association Journal).
https://www.cmaj.ca/content/early/2020/04/08/cmaj.200528
Dr David Juurlink, Division of Clinical Pharmacology and Toxicology, Sunnybrook Health Sciences Centre, and a senior scientist at ICES told Thailand Medical News, "Doctors and patients should be aware of several rare but potentially life-threatening adverse effects of chloroquine and hydroxychloroquine."
The medical review provides an overview of potential harms associated with these drugs as well as their management based on the best available evidence.
Identified potential adverse effects include:
-Cardiac arrhythmias
-Hypoglycemia
-Neuropsychiatric effects, such as agitation, confusion, hallucinations and paranoia
-Interactions with other drugs
-Metabolic variability (some people metabolize chloroquine and hydroxychloroquine poorly and a small percentage metabolize them rapidly, which affects the response to treatment)
-Overdose (chloroquine and hydroxychloroquine are highly toxic in overdose and can cause seizures, coma and cardiac arrest)
-Drug shortages (patients with autoimmune disorders such as rheumatoid arthritis, lupus and other chronic diseases, who take hydroxychloroquine to treat these conditions could have problems accessing this drug)
The review summarizes the poor quality of evidence suggesting that these treatments might not be beneficial in patients with COVID-19 and cautions that it is possible that these treatments could worsen the disease.
Dr Juurlink further added, "Despite optimism (in some, even enthusiasm) for the potential of chloroquine or hydroxychloroquine in the treatment of COVID-19, little consideration has been given to the possibility that the drugs might negatively influence the course of disease. This is why we need a better evidence base before routinely using these drugs to treat patients with COVID-19."
For more on the latest updates for
COVID-19 Clinical Care, keep logging on to
Thailand Medical News
KINDLY HAVE HEART AND HELP! Please help support our site and our initiatives to propel and aid research by making a donation to help sustain the site. Donations are accepted via paypal: https://www.thailandmedical.news/p/sponsorship
